LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 9, 2024, after market hours, Humacyte disclosed that the FDA needed “additional time to complete its review of its Biologic License Application (BLA) for the acellular
Related news